| Compound |
Company |
Primary Therapeutical Area / Indication |
Drug development |
|
| Daivobet® Gel |
|
Skin and Connective Tissue Diseases / Psoriasis |
Phase IV
|
 |
|
|
| ASF-1096 |
|
Skin and Connective Tissue Diseases / Lupus Erythematosus, Discoid |
Phase II
|
 |
|
|
| FP187 |
|
Skin and Connective Tissue Diseases / Psoriasis |
Phase II
|
 |
|
|
| Isoniazide |
Bridge BioResearch
|
Skin and Connective Tissue Diseases / Foot Ulcer |
Phase II
|
 |
|
|
| LEO 22811 |
|
Skin and Connective Tissue Diseases / Psoriasis |
Phase II
|
 |
|
|
| LEO 29102 |
|
Skin and Connective Tissue Diseases / Dermatitis, Atopic |
Phase II
|
 |
|
|
| Valrubicin |
|
Skin and Connective Tissue Diseases / Psoriasis |
Phase II
|
 |
|
|
| Anti-IL20 |
|
Skin and Connective Tissue Diseases / Psoriasis |
Phase I
|
 |
|
|
| LEO 90100 |
|
Skin and Connective Tissue Diseases / Psoriasis |
Pre-clinical
|
 |
|
|
| LEO 90110 |
|
Skin and Connective Tissue Diseases / Psoriasis |
Pre-clinical
|
 |
|
|
| TASS |
|
Skin and Connective Tissue Diseases / Dermatitis |
Pre-clinical
|
 |
|
|
| Mirabegron |
|
Symptoms and General Pathology / Urinary Bladder, Overactive |
Phase III
|
 |
|
|
| Elsiglutide |
|
Symptoms and General Pathology / Diarrhea |
Phase II
|
 |
|
|
| rFXIII |
|
Symptoms and General Pathology / Blood Loss, Surgical |
Phase II
|
 |
|
|
| PPC-5650 |
|
Symptoms and General Pathology / Abdominal Pain |
Phase I
|
 |
|
|
| Mitra |
|
Symptoms and General Pathology / Inflammation |
Pre-clinical
|
 |
|
|
| Solifenacin/Tamsulosin |
|
Urinary Tract, Sexual Organs, and Pregnancy Conditions / Urinary Bladder, Overactive |
Phase IV
|
 |
|
|
| ZP1480 |
|
Urinary Tract, Sexual Organs, and Pregnancy Conditions / Kidney Failure, Acute |
Phase II
|
 |
|
|
| LEO 27847 |
|
Urinary Tract, Sexual Organs, and Pregnancy Conditions / Renal Insufficiency |
Phase I
|
 |
|
|
| IMVAMUNE |
|
Viral Diseases / Smallpox |
Phase III
|
 |
|
|